Browse Prior Art Database

The Design and Synthesis of a Series of ß-Heteroaryl-ß-Amino Acids as Putative Anti-Epileptogenic Agents

IP.com Disclosure Number: IPCOM000004830D
Publication Date: 2001-Jun-26
Document File: 1 page(s) / 21K

Publishing Venue

The IP.com Prior Art Database

Related People

Marcus Brady: CONTACT

Related Documents

09/041,371: PATAPP

Abstract

Epilepsy is a neurologic disorder characterized by spontaneous recurrent seizures arising from abnormal electrical activity in the brain. Commercially available drugs for the treatment of epilepsy are merely symptomatic, diminishing the frequency of seizures rather than affecting the biochemical basis of the disorder. Effective seizure control is achieved for only 60-70 % of those receiving treatment, with 40-45 % of those treated developing side effects ranging from cosmetic to life threatening. Clearly, a need exists for new therapeutic agents with improved efficacy and tolerability.

This text was extracted from a Microsoft Word 97 document.
This is the abbreviated version, containing approximately 100% of the total text.

The Design and Synthesis of a Series of ?-Heteroaryl-?-Amino Acids as Putative Anti-Epileptogenic Agents. A. J. Campbell and D. F. Weavera,b, aDepartment of Chemistry, Queen's University, Kingston, ON. K7L 3N6; bDepartment of Medicine (Neurology), Queen's University, Kingston, ON. K7L 3N6.

Epilepsy is a neurologic disorder characterized by spontaneous recurrent seizures arising from abnormal electrical activity in the brain. Commercially available drugs for the treatment of epilepsy are merely symptomatic, diminishing the frequency of seizures rather than affecting the biochemical basis of the disorder. Effective seizure control is achieved for only 60-70 of those receiving treatment, with 40-45 of those treated developing side effects ranging from cosmetic to life threatening. Clearly, a need exists for new therapeutic agents with improved efficacy and tolerability.

Our research is focused on the design and synthesis of putative small molecule drugs, which simultaneously block the glycine co-agonist site on the excitatory N-methyl-D-aspartate (NMDA) receptor while reducing glial uptake of the inhibitory neurotransmitter ?-aminobutyric acid (GABA). This poster highlights the design and synthesis of a series of ?-heteroaryl-?-amino acids. These compound were prepared in four facile steps starting from the corresponding ?-heteroarylaldehydes. In vivo evaluation of these molecules will also be presented.